Agoracom Blog Home

Archive for the ‘Novamind Inc.’ Category

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:28 AM on Saturday, January 22nd, 2022

The Roundup

A weekly summary of Novamind news and media

Novamind Closes Arizona Acquisition

We are pleased to announce that, further to our press release dated December 23, 2021, we have closed our acquisition of Arizona-based Foundations for Change, Inc., a mental health practice specialized in ketamine-assisted psychotherapy.

“We’re thrilled to welcome the team from Foundations,” commented Novamind CEO and Director, Yaron Conforti. “The Acquisition is an exciting opportunity for Novamind to expand the reach of our clinic network, bringing our model for innovative mental healthcare to a new market in Arizona.”

With the closing of the Acquisition, Foundations founder Jeff Edelman, MSN, APRN, PMHNP-BC, PMHCNS-BC, assumes the role of Medical Director at the Peoria and Phoenix clinic locations.

Mr. Edelman commented: “Joining Novamind is the right fit for our team and aligns with our mission to provide innovative and compassionate mental healthcare. I would like to thank our patients, partners and community for their ongoing support over the years. We look forward to integrating our team and operations with Novamind and benefiting from its deep expertise and infrastructure as we continue to serve a growing patient population.”

Read the full release here.

January 18, 2022

Novamind to Participate in Citi’s Psychedelic Drug Video Call Series

We are pleased to announce our participation in Citi’s Psychedelic Drug Video Call Series to be held virtually on January 25, 2022.

Neena Bitritto-Garg, Vice President Research Analyst, Biotech, at Citi, will host Novamind’s Chief Executive Officer, Yaron Conforti and Chief Medical Officer, Reid Robison, MD, MBA, for a fireside chat at 10:00 AM ET.

“Novamind has an established track record as a leader in commercializing psychedelic medicine and other innovative mental health therapies through a growing network of clinics and hosting an exciting pipeline of clinical trials for major drug developers,” said Mr. Conforti. “I look forward to introducing Citi’s clients to Novamind and expanding our relationships with a global base of institutional investors.”

To register for the call, please contact your Citi representative directly.
 

January 20, 2022

View all press releases

January 18, 2022

Can Psychedelics Change Your Personality?

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison explore whether or not psychedelic medicine can change your personality. They discuss the following: alter states for altered traits, “ego” and how psychedelic medicine can lead to personality changes, and much more.

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

Email us questions and feedback at [email protected].

January 14, 2022

Psychedelic Therapies Continue to Be Seen as Big Trend in Mental Health Treatment

In the latest issue of Mental Health Weekly, Chief Medical Officer Dr. Reid Robison discusses the benefits and barriers of psychedelic treatment and weighs in on the progress of MDMA & psilocybin research and legislative activities in the US.

View all media

Two Thirds of Physicians Surveyed Believe Psilocybin Therapy Has Potential Benefit for Patients With Treatment-Resistant Depression

Perceptions on the potential of psilocybin therapy are shifting in the medical community, according to a recent COMPASS Pathways-sponsored survey. “Severe mental illnesses, such as treatment-resistant depression, have affected too many people in society for too long. Physicians are looking for new approaches to accelerate the healing process, particularly for patients for whom current therapies have failed.” 

MAPS Publishes Open Science Approach to Synthesizing MDMA

A new study by Jay Nair and colleagues from MAPS PBC tries to answer the question of how psychedelic substances will be produced. This is an important step and still, “Many open questions remain about the legal framework that needs to materialize, who will distribute the medicines, and who will be qualified to provide the treatment.” Dr. Robison sat down with Mental Health Weekly for similar conversation.

How Western Medicine Can Adapt to Psychedelic-Assisted Psychotherapy

Lucid News’ Itzhak Beery explores the role of shamanism in Western medicine. “Some psychotherapists feel pressured to offer this type of healing to their clients, who have heard about these magical treatments and hope for a short cut to relief. Most facilitators do not acknowledge the element of spirit or the unseen world.” We’ve also explored this question (and more) in a previous episode of the Psychedelic Frontiers Podcast. Listen to it again here.

For further information, email us: 
[email protected]

We’re hiring!
Check out current opportunities to join our growing team.

Was this email forwarded to you?
Subscribe to our weekly newsletter

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 11:04 AM on Saturday, January 8th, 2022

A weekly summary of Novamind news and media

*The above image is a rendering and may be subject to change.

Novamind Unveils New Design Concept for Clinics

We are pleased to unveil our clinic design concept to accommodate the unique requirements of psychedelic-assisted psychotherapy. The design concept will launch first in Novamind’s Park City, Utah location, and later across Novamind’s de novo clinics. Select design elements and principles will be integrated within existing clinic locations.

Inclusive and welcoming, the design concept enhances the patient experience at Novamind clinics, prioritizing patient safety and privacy, and utilizing evidence-based therapeutic elements to optimize patient care, including:

  • Biophilic designs that mimic nature and emphasize light interplay and neutral colour theory
  • Walking paths designed to minimize disruption and traffic across the clinic, creating a sense of privacy and tranquility
  • Curved treatment spaces, representing the protective space of cocoons, to facilitate the more sedentary experience of ketamine treatment
  • Larger treatment rooms to accommodate group therapy programs and support movement and more active patient behaviours associated with MDMA, psilocybin and other psychedelic medicines when approved by the FDA
  • To create the Design Concept, Novamind contracted DesignAgency, an internationally recognized interior design firm with clients that include the Four Seasons Hotels, MGM Resorts, Momofuku restaurants, Soho House and others. DesignAgency worked closely with Novamind’s clinical team to incorporate a host of therapeutic considerations into the design blueprint to achieve optimal patient experiences.

“We collaborated with Novamind’s clinical team and understood the importance of ‘set and setting’ in psychedelic medicine,” said Matt Davis, Co-Founder and Principal at DesignAgency. “The goal was to create spaces that allow patients to have a holistic experience and signal hope and healing well before they walk through the door.”

Dr. Reid Robison, Chief Medical Officer at Novamind, commented: “This new concept, combined with Novamind’s standard operating procedures, creates the most welcoming and effective healing environment possible. We wanted our clinics to be comforting, inviting and calming. With guidance from the DesignAgency team, we now have the blueprint to create spaces that elevate our patients’ healing experience.”

To see renderings of the Design Concept, click here.

January 5, 2022

View all press releases

January 4, 2022

“What is Integrative Medicine?” with Dr. Amy de la Garza

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by Dr. Amy de la Garza. Amy is the Substance Use Disorder Program Director at Novamind and the Medical Director of the Salt Lake City clinic. Amy is a board-certified family practice physician who for the last 10 years has been providing specialized integrative healthcare for behavioral health, substance use, and a variety of other conditions.

December 29, 2021

Essential Qualities and Skills of the Psychedelic Therapist

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison discuss qualities and skills they think are essential for therapists who provide psychedelic-assisted psychotherapy.

We’re celebrating 8 months of the podcast with a GIVEAWAY on Instagram! Enter to win a sweatshirt featuring the audio waves from a fan-favorite episode of Psychedelic Therapy Frontiers.

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

Email us questions and feedback at [email protected].

December 23, 2021

Novamind Expands To Arizona

Benzinga covers our expansion into Arizona highlighting the signed definitive agreement to acquire the Foundations for Change clinics. 

View all media

Health Canada’s Special Access Program Will Now Allow Doctors To Request Patient Access To Psychedelics

This is big news for Canada overall. “Long-awaited amendments to Health Canada’s Special Access Program have finally been made, potentially opening the door to less onerous access to the medical access of psychedelics like psilocybin and MDMA for patients in need.” Our mission has always been to increase access to these life-changing therapies and drugs in safe and regulated settings. We celebrate this news and will continue to do our part to bring psychedelic medicine to as many people in need as possible.   

Psychedelic Healthcare in 2021

PSYCH covers the year in psychedelic healthcare. “2021 was a seminal year for psychedelic medicine, with data released from groundbreaking clinical trials harnessing MDMA and psilocybin.” 2021 was special, but we can’t wait to work on making 2022 even more impactful for people around the world. For more great psychedelic content from PSYCH, download the third edition of the Psychedelics as Medicine Report here.

Ketamine Therapy Swiftly Reduces Depression and Suicidal Thoughts

Dr. Reid Robison and the team at Novamind have spent years providing ketamine-assisted psychotherapy and seeing the positive benefits firsthand. It’s changed the lives of thousands of our patients. We recently published a story about how ketamine helped a mother struggling with severe depression and a struggling marriage. You can read it here. Seeing the results of this systematic review by the University of Exeter is both exciting and validating. “Ketamine therapy has a swift short-term effect on reducing symptoms of depression and suicidal thoughts, according to a review of all the available evidence.”

For further information, email us: 
[email protected]

We’re hiring!
Check out current opportunities to join our growing team.

Was this email forwarded to you?
Subscribe to our weekly newsletter

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 10:18 AM on Saturday, December 25th, 2021

The Roundup

A weekly summary of Novamind news and media

Dr. Steve Thayer with an important reminder that, for some, the holidays can be a difficult time of year for many reasons. He shares tips to care for our mental health and wellbeing over the holidays.

Watch on Instagram.

Novamind Signs Definitive Agreement to Acquire Arizona-based Clinics

We are pleased to announce the signing of a definitive agreement to acquire Arizona-based Foundations for Change, a mental health practice specialized in ketamine-assisted psychotherapy, from its sole stockholder, Jeff Edelman. The transaction is subject to regulatory approvals and is expected to close in January 2022.

Opened in 2017 by Jeff Edelman, Foundations currently operates one outpatient mental health clinic in Peoria, Arizona with an annual revenue run rate in excess of US$800,000 and owns a second, larger location in Phoenix that is scheduled to open in early 2022. Foundations will temporarily operate as “Foundations for Change by Novamind” until the Company completes its recently announced rebrand. Mr. Edelman will continue in a leadership capacity as Medical Director for both clinics. Mr. Edelman is double board-certified Family Psychiatric-Mental Health Nurse Practitioner and a Child and Adolescent Psychiatric-Mental Health Clinical Nurse Specialist. As a former military combat veteran, who served in the US Army 55th Medical Co. Combat Stress Control unit, Mr. Edelman has special expertise in treating military veterans and first responders who struggle with stress and trauma.

Read the full release here.

December 23, 2021

View all press releases

December 21, 2021

Horizons: Perspectives on Psychedelics Conference Recap

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison catch up after their recent trip to the “Horizons: Perspectives on Psychedelics” conference in New York. Stay tuned next week for our last episode of 2021 and a special PTF podcast contest and giveaway.

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

Email us questions and feedback at [email protected].

With Health Care Workers Hurting, a Doctor Wants to See if a Psychedelic Can Help

NBC News reports on a first-of-its kind clinical trial at the University of Washington School of Medicine to treat 30 medical professionals experiencing depression with a dose of synthetic psilocybin combined with psychotherapy. Some say that even five years ago, this would have been considered taboo. “That medical researchers are turning toward psilocybin to treat colleagues is representative of a growing curiosity and acceptance of the drug among those in the medical establishment.” We’re seeing that openness, too, through our Frontline KAP clinical pilot to help healthcare workers heal.

Psychedelic-Assisted Therapy on the Rise in VA Hospitals

Lucid News covers how research partnerships exploring psychedelic-assisted psychotherapy as treatment option for veterans are gaining traction.

For further information, email us: 
[email protected]

We’re hiring!
Check out current opportunities to join our growing team.

Was this email forwarded to you?
Subscribe to our weekly newsletter

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 10:58 AM on Saturday, December 18th, 2021

The Roundup

A weekly summary of Novamind news and media

December 14, 2021

Psychedelic Inspired Work Life Balance With Jeremiah Robison

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by Jeremiah Robison to talk about work-life balance. Jeremiah is the Founder and CEO of Shroom Beach, a psychedelic-inspired clothing company that donates 10% of its profits to fund psychedelic medicine research

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

Email us questions and feedback at [email protected].

December 15, 2021

Doors Open in SLC

The announcement of our clinic launch in Salt Lake City is featured in Behavioral Health Executive and The Dales Report.
 
Both articles highlight how the new clinic will focus on treating substance use disorders and addiction-related illnesses led by incoming medical director Amy de la Garza.

View all media

Blossom Research Briefing: Eating Disorders

Blossom summarizes the exciting progress made on treating eating disorders with psychedelics. It’s a passion which our Chief Medical Officer, Dr. Reid Robison shares, working for years to bring innovative and effective treatment options to people suffering. Recently, Dr. Robison presented a keynote on the topic at the MindMed Australia International Summit on Psychedelic Therapies for Mental Illness. You can watch it here

Three Canadians With Mental Health Conditions Receive Legal Access to Psilocybin Mushrooms

Three more Canadians received legal access in a big win  that “opens it up to everyone,” but there are still issues with the system overall. “The process is still broken.” The Vancouver Sun explores how even with such positive news, there is still a lot of ground to cover in Therapsil’s fight for expanded access to psychedelic medicine. 

Across the World, COVID Anxiety and Depression Take Hold

No. We are not out of the woods. The Omicron variant is spreading quickly and with it, a slew of public health restrictions and fears reminiscent of March 2020. What can’t get lost in the shuffle again is addressing mental health. Especially for those on the frontlines of healthcare. “This sense of endlessness, accompanied by growing psychological distress leading to depression, was a recurrent theme in two dozen interviews conducted in Asia, Europe, Africa and the Americas. After two years of zigzagging policy and roller coaster emotions, terrible loss and tantalizing false dawns, closing borders and intermittently shuttered schools, people’s resilience has dwindled.” Frontline ketamine-assisted psychotherapy registration is still open for the next group of participants. Learn more here.

For further information, email us: 
[email protected]

We’re hiring!
Check out current opportunities to join our growing team.

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 9:08 AM on Saturday, December 11th, 2021

The Roundup

A weekly summary of Novamind news and media

Novamind Opens New Clinic with Specialized Focus on Substance Use Disorders

Salt Lake City Clinic welcomes incoming addictions specialist, Dr. Amy de la Garza

We are pleased to announce the opening of a new clinic located in downtown Salt Lake City (SLC). In addition to Novamind’s suite of mental health treatments, the SLC Clinic specializes in integrative behavioural health and services for adults with substance use disorders (SUD) led by incoming Medical Director, Dr. Amy de la Garza.

The SLC Clinic’s outpatient SUD services provide an alternative to residential treatment programs and work to address the highly complex public health crisis that is worsening alongside challenges related to access. In 2020 alone, 93,000 Americans died of a drug overdose-an increase of 30 per cent from the previous year, according to the Centers for Disease Control and Prevention.

Dr. Reid Robison, Novamind’s Chief Medical Officer, commented: “Social isolation and despair related to the COVID-19 pandemic have further fueled a significant increase in substance use disorders and related deaths. Dr. de la Garza’s expertise in addiction medicine and behavioural health is a vital addition to our team as we continue to expand Novamind’s clinic footprint to address unmet need and broaden our innovative, evidence-based treatments.”

Dr. de la Garza is a board-certified family practice physician with 10 years of experience providing specialized care for patients with behavioral health and SUD diagnoses. She earned her Doctorate in Medicine from the University of Colorado before completing a Family Medicine Residency at the Utah Healthcare Institute. She also completed an Addiction Medicine Fellowship at the University of Utah and is an Institute for Functional Medicine Certified Practitioner. In 2017, Dr. de la Garza opened the first community-based, co-located primary care and behavioral health practice in Salt Lake City, Utah.

“I am thrilled to join Novamind and look forward to establishing an innovative outpatient substance use disorder program that brings together addiction and integrative medicine and treats the whole person,” said Dr. de la Garza, who is also trained in integrative modalities and lifestyle medicine, including nutrition, movement, sleep, stress management and social connection.

Novamind will collect clinical data on the efficacy of the integrative treatment approach for SUD and host upcoming studies for conditions like opioid use disorder. Additionally, the SLC Clinic will pilot an innovative and cost-effective group medical visit model that has been shown to reduce anxiety and depression, as well as improve outcomes in chronic conditions like cardiovascular disease and diabetes.

The SLC Clinic is located at 807 E South Temple, Suite 101, Salt Lake City, Utah.

December 6, 2021

View all press releases

December 7, 2021

Anxiety: Why We Worry and What to Do About It

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison explore anxiety. They discuss the following topics and much more:
• What is an anxiety disorder?
• Anxiety management skills
• The role of medicines in treating anxiety

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

Email us questions and feedback at [email protected].

December 10, 2021

Ketamine-Assisted Therapy Is Having a Moment in Utah

Utah Business covers Dr. Reid Robison and the success of ketamine-assisted psychotherapy in our clinics. “While it’s still early and much more testing is to be done, Robison describes what’s happening in mental health care as a ‘psychedelic renaissance’.”

December 9, 2021

Doors Open in SLC

Benzinga covers the opening of our Salt Lake City clinic and future substance use disorder program led by Dr. Amy de la Garza.

December 9, 2021

Panel: International Summit on Psychedelic Therapies

Dr. Reid Robison, Matt Johnson and Robin Carhart-Harris discuss The Science of Psychedelics: Therapeutic mechanisms and clinical outcomes for a range of mental illnesses and other conditions.

December 8, 2021

Psychedelics & Eating Disorders

Chief Medical Officer Dr. Reid Robison’s keynote presentation at the Mind Medicine Australia International Summit on Psychedelic Therapies for Mental Illness.

View all media

Opioid Overdoses Are A Raging Public Health Crisis, Driven Mostly By Illicit Fentanyl And Heroin

“While the U.S. has been battling Covid-19 it’s gotten lost in the shuffle that the nation had record numbers of drug overdose-related deaths in 2020; approximately 93,000. In addition, from May 2020 through April 2021, the figure rises to 100,000.” We need better treatment options for people with substance use disorders (SUD). It’s the driving force behind why incoming Novamind Medical Director Dr. Amy de la Garza will lead SUD programming at our new Salt Lake City clinic.  

Psychedelics are Poised to Change the Course of Mental Health Treatment

We are currently in a mental health crisis. Depression, anxiety and symptoms of PTSD have run rampant over the last two years, accelerated by the COVID-19 pandemic and its far-reaching effects. The need for new and effective mental health treatments has never been clearer. We have seen the efficacy of ketamine-assisted psychotherapy firsthand. And we are eager to continue psychedelic research. If you’d like to stay up to date on upcoming studies hosted by Novamind, visit us here and get in touch. “So what else does the future hold for psychedelics? For one thing, taking psychedelics could one day be the same as taking an everyday pill prescribed by your doctor.”

For further information, email us: 
[email protected]

We’re hiring!
Check out current opportunities to join our growing team.

Was this email forwarded to you?
Subscribe to our weekly newsletter

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 9:19 AM on Saturday, December 4th, 2021

A weekly summary of Novamind news and media

Novamind Reports Fiscal Q1 Financial Results and Operating Highlights​

  • Multistate expansion underway, signed LOI to acquire Arizona-based mental health practice
  • Total revenue of $1,857,750, +113% when compared to same period last year
  • Total working capital of $6,834,011 to fund operations

“Q1 was a strong start to fiscal year 2022, driven by the addition of another clinic to our network and increased patient demand for our comprehensive range of innovative mental health treatments,” said Yaron Conforti, Novamind’s CEO and Director. “We continue to make progress on our national clinic expansion, most recently with a letter of intent to acquire two locations in Arizona. Our clinical research business has been actively building an exciting pipeline of contracts with leading drug developers.” 


Nov 29, 2021

Novamind Partners with Uruguay-Based Bienstar Wellness to Develop Latin America’s First Integrative Mental Health Clinic Network​

“Novamind operates best-in-class psychiatry clinics and clinical research sites, with a proven ability to replicate our clinic model in the U.S. Our agreement with Bienstar is an exciting opportunity to export our clinical expertise and capabilities into international markets,” said Yaron Conforti, Novamind CEO and Director. “Partnering with local operators allows us to disseminate Novamind’s best practices and SOPs globally, with minimal investment and managed risk, ultimately expanding access to psychedelic medicine and innovative mental healthcare on a global scale.”


Dec 1, 2021

Novamind to Present at the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6​

Novamind’s CEO and Director, Yaron Conforti, will join the Psychedelics Assisted Psychotherapy panel discussion from 1:30 PM to 2:15 PM EST. Mr. Conforti will also deliver a corporate presentation to update investors on recent milestones and progress towards the global expansion of Novamind’s psychedelic clinics and research sites.

For more information about the event and to register, visit https://hcwevents.com/psychedelics.


Dec 2, 2021

View all press releases

November 30, 2021

Taking the middle way in a polarized world​

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison explore the concept of the “middle way” and the need for balance in an increasingly polarized world.

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

Email us questions and feedback at [email protected].

Psychedelics Can Change Humanity for the Better. It’s Time to Unlock Their Power

In a piece for The Guardian, psychedelic pioneer Rick Doblin explains how psychedelics can change humanity for the better. “We envision a day when psychedelics will be more than a last-ditch treatment: they will be a catalyst for mass mental health.” 

The Promise and Pitfalls of Psychedelics

The work to destigmatize psychedelics has been long and arduous. Just ask Rick Doblin. He’s devoted his life to it. But as more and more research comes out, more and more people are changing their opinion on the once villainized substances. “Public attitudes around psychedelics are shifting: A recent Nanos Research survey, commissioned by the Canadian Psychedelic Association, found that 82 per cent of Canadians are in favour of psilocybin-assisted therapy in end-of-life illness, while 78 per cent of those polled support legalizing it to improve the quality of life for palliative and end-of-life patients.”

For further information, email us: 
[email protected]

We’re hiring!
Check out current opportunities to join our growing team.

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 10:13 AM on Saturday, November 27th, 2021

A weekly summary of Novamind news and media

Novamind Unveils New Logo and Invests in Unified Brand

We are pleased to launch our new logo and announce that the Company will unite its subsidiaries and brands under a single Novamind brand.

Novamind is investing in a revitalized and unified brand following a year of significant growth including expansion into new states, launching new clinics and research sites and bringing to market several innovative mental health care offerings.

Novamind’s new logo is now live on its corporate website and social media platforms. The logo integrates and flows across all digital and physical properties, and represents Novamind’s core beliefs in hope, healing and transformation. The open doorway at the centre of the logo, working in conjunction with the radiating lines, is an invitation towards an improved way of life—one where taking care of mental health is a priority.

The logo reveal kicks off the multi-phase rebrand of the Company’s network of clinics and research sites, expected to be complete in 2022. The Company is also improving its website to scale alongside its growth strategy and better serve diverse audiences with enhanced content and tools. Taking inspiration from the revitalized logo, the website will provide an accessible digital entry point to Novamind’s world-class care and clinical research offerings.

Yaron Conforti, CEO and Director, commented: “The new logo, rebrand and website reflects our rapid evolution over the last year. It’s an exciting opportunity to unify our current and future assets under one unique identity that will become a trusted and recognized name for innovative mental healthcare in communities across the U.S.”

Nov 24, 2021

View all press releases

November 23, 2021

Navigating Spiritual Emergencies with Hannah Cross

In this episode of the Psychedelic Therapy Frontiers podcast, Hannah Cross is back and joinsDr. Steve Thayer and Dr. Reid Robison to explore psycho-spiritual emergencies. Hannah is a licensed clinical social worker, therapist, reiki master and yoga teacher. 

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

Email us questions and feedback at [email protected].

Could MDMA-Assisted Therapy Be a Treatment for Alcohol Use Disorder?

Could MDMA-assisted therapy be a treatment for alcohol use disorder? A new study says psychotherapy under the influence of the drug MDMA could help patients process the traumatic experiences that are often the root cause of this condition. Psychedelics have long been considered in the treatment of alcohol use disorder, with scientists in the ‘60s hypothesizing that it might. Click the link above to learn more about MDMA and alcohol use disorder. Learn more about LSD and alcohol use disorder here.

Psychedelic Therapy Is Poised to Create a Revolution in Mental Health, Can VR Accelerate It?

Virtual reality could be the next great digital frontier. And thinking has already begun for how it can advance the mental health revolution we are currently in. “The use of VR in medical settings to provide emotional care is not a new concept. Over the past several years VR has been employed with greater frequency and effectiveness in ways large and small. Recently, the staff at a hospital in Long Beach, California, used virtual reality tech in a simple yet valuable context, distracting young patients during medical procedures like removing a cast.”

5 Genes That May Affect Your Reaction to Psychedelic Drugs Like ‘Magic’ Mushrooms and LSD

Your genetics may hold some clues as to how psychedelics might affect you. But the test isn’t perfect and results should be taken with a grain of salt: “The test covers five different DNA markers for psychedelic sensitivity, metabolism, and mental health risk. However, some of the conclusions drawn by HaluGen are oversimplified or based on outdated science, experts told VICE.”

Michael J. Fox Foundation Grant Will Fund First Clinical Trial of Ketamine to Treat Depression in People With Parkinson’s Disease

Researchers from the Yale Department of Psychiatry were awarded a US$2 million grant for a first-of-its-kind clinical trial. “Holmes and Sanacora will compare the efficacy of ketamine (six infusions administered intravenously over three weeks) to placebo in 50 individuals with Parkinson’s disease and depression. Using cutting-edge brain imaging they will also study the mechanistic effects of ketamine on synaptic connections and functional networks in the brain.” In a similar vein, we recently launched the Psychedelic Palliative Care by Novamind program earlier this fall. It’s a program that supports the mental health of adults coping with serious or chronic physical illness such as cancer, heart disease, Parkinson’s or pain conditions. Learn more here.

For further information, email us: 
[email protected]

We’re hiring!
Check out current opportunities to join our growing team.

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:57 AM on Saturday, October 16th, 2021

A weekly summary of Novamind news and media, including the announcement we have been granted DEA licenses for psilocybin research.

October 12, 2021

Psychedelics, Mindfulness, and Contemplative Practices

In this episode of the podcast, Dr. Steve Thayer and Dr. Reid Robison are joined for the second time by Dr. Paul Thielking, MD. He is a psychiatrist, zen practitioner, and Chief Scientific Officer at Novamind. 

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

Email us questions and feedback at [email protected].

October 15, 2021

Why Palliative Care?

Chief Scientific Officer, Dr. Paul Thielking speaks with Amanda Siebert from The Dales Report on the potential of psychedelics for palliative care and the role of group therapy.

October 15, 2021

The Most Effective Pairing

In a recent interview with Technology Networks, Dr. Reid Robison spoke about the powerful combination of psychedelics and psychotherapy. 

October 14, 2021

A Key Step in Hosting Contracted Clinical Trials for Psilocybin Research

Chief Medical Officer, Dr. Reid Robison discusses Novamind being granted DEA licenses for psilocybin research and our new Psychedelic Palliative Care program with AGORACOM.

October 7, 2021

“We’re Just Scratching the Surface of What Can Be Done.”

Dr. Reid Robison opened the PSYCH Investor Summit with a keynote address presenting Novamind’s positioning and the rise and rollout of psychedelic medicine.

Don’t forget to download the third edition of PSYCH’s “The Psychedelics as Medicine Report”, featuring an expert interview with Dr. Robison.

View all media

Novamind Granted DEA Licenses for Psilocybin Research

We are pleased to announce we have been granted Schedule 1 licenses (the “DEA Licenses”) from the U.S. Drug Enforcement Agency (DEA) for Dr. Reid Robison, Chief Medical Officer, and Dr. Paul Thielking, Chief Scientific Officer. The DEA Licenses are required for research sites planning to host clinical trials for psilocybin, enabling principal investigators to store and administer this controlled substance.

“Obtaining the DEA Licenses is a critical step towards hosting clinical trials for psilocybin-assisted psychotherapy,” commented Dr. Robison. “We’re proud of our clinical research organization’s track record investigating innovative solutions for central nervous system conditions. This milestone reflects our expertise and enables us to continue on our mission to create breakthroughs in mental health treatment.”

Psilocybin has shown significant positive outcomes for people with major depressive disorder¹ and for reducing anxiety and depression in people with life-threatening cancer.² As of today, there are over 50 clinical studies actively examining the use of psilocybin, as listed on www.clinicaltrials.gov.

“The DEA Licenses are timely,” said Dr. Thielking, who last week launched Psychedelic Palliative Care by Novamind, a first of its kind program to support the mental health of patients and families struggling with serious illness. “We anticipate that this progress will accelerate the approval process for us to become a research site for additional psychedelic clinical studies in the future.”

To learn more about Novamind’s clinical research division, visit www.cedarclinicalresearch.com.

¹ https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2772630
² https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367557/

October 13, 2021

View all press releases

How COVID-19 Opened the Door to a New Era in Psychedelic Medicine

Time magazine writes how the burnout, trauma and stress caused by the COVID-19 pandemic is opening the door to accelerated psychedelic research. “It’s no coincidence that psychedelics are entering the conversation at the moment we most sorely need new ideas in mental health care. The world is experiencing mass trauma from COVID-19.” It’s especially true with frontline workers. The stats are alarming. The need has never been more apparent. It’s why we launched our Frontline Ketamine-Assisted Psychotherapy treatment program earlier this year. We’re providing healthcare workers with critical mental healthcare. You can learn more about the program here.

Will Australia Take a Lead in Psychedelic Therapy?

Therapeutic Goods Administration (TGA) in Australia is currently evaluating a proposal to reschedule two prominent psychedelics into a less restrictive classification. Mind Medicine Australia submitted the proposal to the government and “has the support of world leading experts in psychedelic research.” 
Novamind Chief Medical Officer, Dr. Reid Robison, will be presenting at the Mind Medicine Australia summit in November. Get your tickets here.

The New Cannabis?

Could psychedelics follow the same path of cannabis toward legalization and regulation for medical purposes? It’s a question Luis Millán asks for National Magazine. “Despite the legal uncertainty, business is hopeful. Some stock market speculators believe psychedelics will follow in the footsteps of the cannabis industry and become the next billion-dollar business.”

Follow @novamind_inc on Instagram

For further information, email us: 
[email protected]

Was this email forwarded to you?
Subscribe to our weekly newsletter

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:56 AM on Saturday, October 9th, 2021

A weekly summary of Novamind news and media, including the launch of our new Psychedelic Palliative Care program.

October 5, 2021

Self Compassion, Forgiveness, and Judgment Detox

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison discuss self-compassion, why it is so hard (but so important) to forgive, and how to detox from judgement.

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

October 6, 2021

Novamind Today and Into the Future

CEO Yaron Conforti at the Benzinga Healthcare Small Cap Conference on the progress we’ve been making to increase access to psychedelic medicine.

October 6, 2021

Addressing Mental Health through Emerging Therapies Panel

CEO Yaron Conforti joins a panel of industry leaders at the Benzinga Healthcare Small Cap Conference for this informative discussion.

October 7, 2021

Dr. Reid Robison Keynote at PSYCH Investor Summit

Novamind’s Chief Medical Officer opened the Summit with a keynote drawing on his career as a pioneering psychiatrist and researcher in ketamine-assisted psychotherapy. Check back next week for footage of his presentation.

In addition, we are pleased to be featured in the third edition of PSYCH’s “The Psychedelics as Medicine Report”.

View all media

Novamind Launches New Psychedelic Palliative Care Program

We are pleased to launch Psychedelic Palliative Care by Novamind (the “Palliative Program”) at its recently opened clinic and research site in Murray, Utah.

Among the first-of-its-kind, the Palliative Program combines psychedelic medicine with psychotherapy, workshops, multi-day immersive retreats and group support for palliative care patients and families who are coping with chronic and serious illness.

“Patients receiving palliative care have higher rates of depression than the general population. Unfortunately, standard anti-depression and anti-anxiety treatments do not work for everyone, can cause side effects, and can take up to eight weeks to work,” explained Dr. Paul Thielking, Chief Scientific Officer (CSO) of Novamind. “Due to psychedelic medicine’s generally low side effect burden and fast-acting nature, it shows promise for patients who are physically ill and might have limited life expectancies.”

Through Novamind’s clinical research division, the Palliative Program will host studies to investigate the use of psychedelic medicine including ketamine and establish the infrastructure for future clinical studies examining psilocybin. This work will build on notable studies from New York University and Johns Hopkins University, which demonstrated psilocybin’s significant immediate and sustained improvements in anxiety and depression symptoms in cancer patients.

Prior to his role as Novamind’s CSO, Dr. Thielking developed ketamine-assisted treatment protocols for cancer patients experiencing depression at the University of Utah Huntsman Cancer Institute (HCI). He also pioneered an ongoing HCI study examining the feasibility of group-administered psilocybin-assisted psychotherapy for cancer patients experiencing depression. Dr. Thielking leads the Palliative Program’s multidisciplinary team of mental health professionals specialized in palliative care and psychedelic-assisted psychotherapy.

“Our healthcare system struggles to support the millions of Americans dealing with emotional, spiritual and psychological suffering associated with chronic or serious illness,” noted Dr. Thielking. “Psychedelic Palliative Care by Novamind is designed to address this need, bringing together fast-acting medicine, innovative treatment options and therapeutic expertise in a safe, nurturing environment.”

To learn more about the Palliative Program, visit www.novamind.ca/psychedelic-palliative-care

October 7, 2021

Novamind to Present at LD Micro and KCSA Conferences

We announced our participation in two upcoming virtual investor conferences on Wednesday, October 13, 2021.

Novamind’s CEO and Director, Yaron Conforti, will present our progress towards expanding access to psychedelic medicine in the U.S., including the recent opening of our sixth clinic and the newly launched Psychedelic Palliative Care program.

Virtual LD Micro Main Event XIV
Date: October 13, 2021
Time: 10:30 AM to 11:00 AM EST
Register and watch live here: me21.mysequire.com

KCSA Psychedelics Virtual Investor Conference
Date: October 13, 2021
Time: 1:00 PM to 1:30 PM EST
Register and watch live here: www.virtualinvestorconferences.com/events/event-details/psychedelics-virtual-investor-conference

October 8, 2021

View all press releases

The Psychedelics Industry Could Offer a Whole New Approach to Work

In a collaboration with DoubleBlind magazine, Shelby Hartman and Madison Margolin explore how professional and economic systems are changing as the psychedelic revolution continues to grow. It’s not just about growth, though, but also the way we work. “What psychedelics offer is an invitation to look at professional and economic systems more, well, psychedelically.”

Psychedelics: Psychiatry of the Future

Covering Rick Doblin’s talk at the 2021 Annual Psychiatric Times World CME Conference, Leah Kuntz writes about what other conditions MDMA could treat including “depression, alcohol dependence, obsessive compulsive disorder, and even demoralization in AIDS survivors.” We look forward to further research on MDMA and will work to create treatment protocols for an array of mental health conditions, similar to our work with ketamine.

How Psychedelics are Returning to the World of Medicine

“According to estimates by the World Health Organization, about 300 million people worldwide live with depression.” It’s a stat that illuminates why there is so much urgency to bring psychedelic-assisted therapies to the world. We want to make a difference, to improve the quality of life for people suffering from depression and other mental health conditions, regardless of the psychedelic being used to bring about that lasting change. From Chief Medical Officer, Dr. Reid Robison: “I’m always touched by stories of hope and healing that come from witnessing the psychedelic modalities in action.”

Follow @novamind_inc on Instagram

For further information, email us: 
[email protected]

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 9:29 AM on Saturday, October 2nd, 2021

A weekly summary of Novamind news and media, including the announcement of the opening of our 6ᵗʰ clinic in Murray, Utah.

September 28, 2021

Fear, Suffering, and the Value of Struggle

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison discuss fear, the difference between pain vs. suffering, and the value of struggle in life.

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

September 28, 2021

Dr. Reid Robison presents at the Life Sciences Investor Forum

In case you missed the presentation from our Chief Medical Officer, a recording of the presentation is now available for viewing here.

October 1, 2021

The Rapid Expansion Continues

Novamind CEO, Yaron Conforti, sits down with Agoracom to discuss opening our 6ᵗʰ clinic in Murray, UT and the broader vision for the company.

View all media

Novamind Opens 6ᵗʰ Integrative Psychiatry Clinic, Adds 3ʳᵈ Clinical Research Site

We are pleased to announce the opening of our sixth integrative psychiatry clinic. The clinic is in Murray, Utah (the “Murray Clinic”).

The Murray Clinic also serves as Novamind’s third clinical research site, further strengthening the Company’s capabilities for serving drug developers via multiple sites and access to a large patient population. The Company anticipates 65,000 visits to its clinics this year.

“Bringing cost-effective and innovative psychedelic therapies to market requires a large base of diverse candidates and the expertise to safely and effectively run complex clinical trials in the right environment,” explained Yaron Conforti, CEO and Director. “We continue to build on our model’s proven track record through the expansion of our clinics and research sites, and we expect to scale this unique operating model into additional states in the near term.”

The Murray Clinic is the latest in Novamind’s ongoing clinic expansion, with two additional clinics slated to open in Utah by the end of 2021. The Salt Lake City location is scheduled to open in October, while the Park City location will open in November to accommodate the construction of the Company’s new flagship clinic design.

Learn more about Novamind’s clinical research division here.

September 30, 2021

View all press releases

How Psychedelics Changed my Life

The evidence continues to grow in support of psychedelic medicine. In a piece for the Independent, Jonathan Sabbagh writes about how psychedelics, and ketamine-assisted psychotherapy in particular, changed his life. “For the first time, I understood the truth. My burnout wasn’t an end in itself. It was a symptom of a previously undiagnosed severe case of post-traumatic stress disorder.”

The Science of Psychedelic Therapy Breaks on Through

Axios breaks down why psychedelics matter, where they stand and what to watch for in the future. “Scientific studies of psychedelic therapies may be entering a new, broader phase thanks to more interest and funding from federal governments.” We will continue to research psychedelics and other innovative therapies at Cedar Clinical Research. CCR’s research sites are co-located with Novamind’s Cedar Psychiatry clinics allowing for large client population recruitment and providing clients access to innovative research stage treatments. And just this last week, we announced the opening of a new research site and clinic.

Follow @novamind_inc on Instagram

For further information, email us: 
[email protected]